Thrive Focus:Personalized Medicine – Institutionalizing Diabetes Care for BetterPatient Outcomes
Spokane, WA â€“ TheNewswire – November 17, 2023 â€“ Thrive PrecisionHealth (“THRV”) (formerly Thrive Global Biosafety and ChinaNew Energy Group Company (with subsidiary Thrive Testing and BiosafetyInc., “CNER” or “Company”) (OTC:CNER) is pleased to announce it has entered into an agreement toacquire all of the assets of two diabetes clinics in Hawaii with theplan to expand to 20 clinics.
“Diabetes is a big problem among the population inHawaii, and our focus will be to reduce the pain, struggle, and costof the diabetes epidemic and its co-morbidities.”, stated GuyZajonc, CEO and Chairman of Thrive Precision Health.””Acquisition of Heal Diabetes, Inc. will give us the footprint tobuild Thrive Clinics across Hawaii. The management team is highlyskilled in delivering the newest forms of diabetestreatment.”
Heal Diabetes has 2 locations operating and has billed$1.2M in diabetic care service year to date in 2023 and is seeingconsistent month-over-month growth. Over 350 patients have beentreated in 2023 at the Honolulu HI and Waipahu HI clinics. We plan toopen two more clinics in early 2024. The first one in Waipahu toaccommodate a waitlist of 200 patients. Â Â And the second new clinicin Waianae, HI, to serve over 4,500 diabetic patients through networkreferrals.
“The Thrive Precision Health vision to applyadvanced technology to diabetes care and individualizing eachpatient’s care is the next evolutionary step in digital health. Whenadvanced technology focuses on a specific problem as large asdiabetes, we believe patient outcomes will be better by avoidingexpensive treatments like amputation, dialysis, and chronicpain,” stated Charles Elliott, President of Heal Diabetes.”Our experience in delivering care on the front lines combinedwith Thrive’s technology is something my team wants to be partof.”
THRV will start with the two operational clinics andwork to fund the startup of the next two clinics in Q1 2024. Based ondemographics and demand, THRV expects to serve the diabetic communityacross Hawaii with 20 clinics. Each clinic will have a standardizedfootprint with digital workflows to guide patients and clinicians onoptimal care procedures.
The Hawaii State Department of Health, in theirPublished Hawaii Diabetes Plan 2030, states, “Diabetes costsHawai’i $1.1 billion in direct healthcare expenditures and iscurrently the 8th leading cause of death in the state. Nearly one inevery four healthcare dollars goes toward the care of people withdiabetes. On average, people with diabetes incur more than twice themedical costs of people without diabetes.
For more details on the report, click the linkbelow:
The acquisition is an asset purchase transaction is anall-stock acquisition and will close once Thrive Precision HealthHawaii Inc. (a wholly owned subsidiary of Thrive Precision HealthInc.) completes its mandatory credentialing in Hawaii, estimated to be90-120 days. During this hold period, THRV will advance funds to HealDiabetes to expand their operations and add the two newlocations.
Thrive Precision Health Inc., has made an applicationto FINRA for a name and symbol change as it appears on the OTC Marketsweb site (currently reported as China New Energy Group Company,OTC:CNER). Â Corporately the name has been changed in the State ofDelaware and legally operates as Thrive Precision Health Inc.
About Thrive Precision HealthInc.
Thrive Precision Health, Inc. (“Thrive”) isbuilding a global diabetes care powerhouse. We are starting oracquiring established healthcare clinics specializing in diabetes careand bringing in three cutting-edge technologies to make them evenbetter. Our goal is to provide top-notch care to patients worldwidewith a seamless digital experience. Imagine if your healthcare was asunique as you are. We use AI and quantum biosensors to analyze datadown to the molecular level, tailoring treatments and recommendationsspecifically for you. This means no more one-size-fits-all solutions.Your health decisions will be based on your personal data, ensuringyou receive the most effective and personalized care possible.Leveraging this groundbreaking technology and clinical services willinclude Wound Care, Neuropathy Care, PIR diabetes care throughadvanced infusion methods, and conventional and complementarytreatment to improve patient outcomes. All services will be performedwithin a biosafety-secured facility using our biodefense technology toprotect our suspectable patients and staff from bacterial and viralinfections.
Important Notice RegardingForward-Looking Statements
This press release contains statements that constitute”forward-looking statements” within the meaning of Section27A of the Securities Act of 1933, as amended (the “SecuritiesAct”), and Section 21E of the Securities Exchange Act of 1934, asamended (the “Exchange Act”). All statements, other thanstatements of present or historical fact included in this pressrelease, regarding the Company’s future financial performance, as wellas the Company’s strategy, future operations, revenue guidance,projected costs, prospects, plans, and objectives of management areforward-looking statements. When used in this press release, the words”could,” “should,” “will,””may,” “believe,” “anticipate,””intend,” “estimate,” “expect,””project,” the negative of such terms and other similarexpressions are intended to identify forward-looking statements.However, not all forward-looking statements contain such identifyingwords. These forward-looking statements are based on management’scurrent expectations and assumptions about future events. They arebased on currently available information as to the outcome and timingof future events. Except as otherwise required by applicable law, theCompany disclaims any duty to update any forward-looking statements,all of which are expressly qualified by the statements in thissection, to reflect events or circumstances after the date of thispress release. Nothing in this release is intended to be an offer ofsale or purchase of any securities nor a solicitation of any offer forthe sale or purchase of any securities.
China New Energy Group Company/Thrive Precision HealthContact:
U.S. +1 (509) 230-1177
Copyright (c) 2023 TheNewswire – All rights reserved.
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of China New Energy Grp Co (CNER) and does not buy, sell, or trade any shares of (CNER). This article does not provide a professional analysis of a (CNER) financial position. (CNER) financial position and all other information regarding the featured Company should be verified directly with (CNER). Please read our full disclaimer for more detailed information.